Table 3.
Pharmacokinetic parameters of sCT after application via different delivery routes in hairless rats (n=4).
| Delivery Route1 | Formulation | AUC (ng/mL.min) | Cmax (ng/mL) | Tmax (min) | Fabs (%) 2 | Frel (%) 3 |
|---|---|---|---|---|---|---|
| IV | Commercial (IV) | 389±131 | 10.5±7.0 | 5 | - | - |
| SC | Commercial (IV) | 403±253 | 8.0±2.9 | 15 | 104±65 | - |
| IN | Commercial (IN) | 18.4±14.5 | 0.38±0.47 | 61±53 | 4.7±3.7 | 4.6±3.6 |
| Skin | MN1 | 154±79 | 3.8±3.2 | 15 | 39.6±20.2 | 38.2±19.5 |
| Skin | MN2 | 250±83 | 6.5±2.6 | 7.5±5.0 | 64.3±21.5 | 62.0±20.7 |
| SC | MN1 | 267±181 | 2.0±0.9 | 30±15 | 68.7±46.6 | 66.3±45.0 |
| SC | MN2 | 229±131 | 2.3±0.1 | 45±15 | 58.9±33.8 | 56.8±32.6 |
1
IV: intraveneous. SC: subcutaneous. IN: intranasal.
2
Fabs: absolute bioavailablity (relative to IV injection)
3
Frel: relative bioavailability (relative to SC injection)